Cytek Biosciences (CTKB) Non-Current Deffered Revenue (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Non-Current Deffered Revenue data on file, last reported at $17.7 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deffered Revenue rose 12.44% year-over-year to $17.7 million; the trailing twelve-month figure through Mar 2026 stood at $17.7 million (up 12.44% YoY), and the FY2025 full-year result was $18.3 million, up 13.92% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $17.7 million, down from $18.3 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $18.3 million in Q4 2025 and bottomed at $7.2 million in Q1 2022.
• The 5-year median for Non-Current Deffered Revenue is $15.1 million (2023), against an average of $14.5 million.
• The widest annual swing landed in 2023, when Non-Current Deffered Revenue jumped 80.75%; it then slipped 12.4% in 2024.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $13.1 million in 2022, then rose by 15.3% to $15.1 million in 2023, then rose by 6.38% to $16.1 million in 2024, then advanced by 13.92% to $18.3 million in 2025, then slipped by 3.64% to $17.7 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $17.7 million (Q1 2026), $18.3 million (Q4 2025), and $16.3 million (Q3 2025), per Business Quant data.

Peer Comparison